Summary of the evening event17 Jun 2020 13:48
interesting summary of tonight event
The spread of the SARS-COV-2 (COVID-19) pandemic is driving an urgent need for extensive testing, in order to quickly and accurately assess both who is infected, and who has been infected. In order to reach the scale of testing needed, a dual approach of both reverse transcription polymerase chain reaction (RT-PCR) molecular tests and lateral flow based tests needs to be implemented. This session will discuss the design challenges encountered during COVID-19 rapid point of care (POC) diagnostic test development, and the solutions that exist to overcome them.
Learning Objectives:
1. Understand current COVID-19 diagnostic technologies
2. Why a dual approach of both RT-PCR and lateral flow based tests is needed
3. Design challenges you need to be aware of when developing a COVID-19 lateral flow test
4. What support exists to help developers overcome design challenges
So what is clear is that Cyteva are presenting the NEED for a lateral flow test , highlighting deign requirements, and solutions to overcome any design challenges. This is not specifically about Avacta per se - but given the speakers below including Avacta - shows we are in bed at the right time with the right partners.
ALL GOOD
SPEAKERS
Klaus Hochleitner, PhD
Global Technology Lead, Diagnostics, Cytiva
Biography
Brendan O'Farrell, PhD
President and Co-Founder, DCN Diagnostics
Darren Rowles
President and CEO, Sona Nanotech
David Wilson
Commercial Director, Diagnostics, Avacta Life Sciences
Moderator: Lee Jenkins
Senior Product Leader, Cytiva